Charity registration number 1137689 {England and Wales) Charity registration number SC049777 (Scotlandl Company rgglstratlon numbgr 07272699 {England and Wal9$1 PANCREATIC CANCER ACTION ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023
PANCREATIC CANCER ACTION LEGAL AND ADMINISTRATIVE INFORMATION Trusts9S N Menezes R Legg C Carter E Cowan N Longworth L Nylander G Codacci Pisanelli (Appointed 18 March 20241 D Slaler (Appointed 18 March 20241 G Lesca (Appointed 18 March 20241 Se¢rotsry G Brown (Resigned 12 January 20231 Charlty numb&r (England and Wales} 1137689 Charlty number (Scotlandl SC049777 Company number 07272699 Registered office BASE Bordon Innovation Centre Broxhead House 60 Barbados Road Bordon GU35 OFX Audltor Alliolls LLP 3 London Square Cross Lanes Guildford GU1 1UJ
PANCREATIC CANCER ACTION CONTENTS Pagg CEO'S report Trustees. report Independent auditorfs report 9-11 Stslemenl of financial activities 12 Balance sheet Stslemenl of cash flows 17 Notes lo the financial ststemenls 14-26
PANCREATIC CANCER ACTION CEO'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 The year 2023 was one of change and growth for Pancreatic Canr Action while Continuing to champion the voice of patients and families, support individuals in a lime of crisis and campaign ID improve earfy diagnosis and save lives. During the year we welcomed a new Chief Executive for the first lime in thirteen years, we delivered our largesl-ever digital symptom awareness campaign, we supported a record number of patients and families, we rebuilt relationships with volunteers and our wider community and we delivered major system changes through our lobbying and campaign work. We are righuy very proud of our achievements.. however, we know that there is still a great deal of work remaining to be done if we are ID improve pancreatic cancer survival rates and save lives. This means we will have to redouble our efforts in all areas if we are to finally improve the care for patients and get people diagnosed in time for life-saving surgery. 11 is worth noting that as an organisalion Pancreatic Cancer Action could not operate al the same level wilhoul the hard work and dedication of our volunteers. They fulfil such varied roles from campaigners and fundraisers lo reviewing our patient information booklets and of course, serving on our Trustee Board or as Ambassadors. Imthout our volunteers. hardworking staff team. patients and families we could not do what we do. Looking forward to 2024 we plan to build on that proud record of growth and activity we establish in 2023. Vve shall do this through investing more in research, creating new resources lo support patients, recruiting more volunteers, delivering innovative campaigns and promoting our resources for healthcare professionals. We look forward to fighting for each and every patient and their families. Joe Kirwin Chief Executive Dated.. .Q.fjJQ912Q24......
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees present their annual report and financial slalements for the year ended 31 December 2023. The financial slalements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005. the Charities Accounts Iscotlandl Regulations 2006 las amended) and 'A¢counling and Reporting by Charities.. Stslemenl of Recommended Pra¢ti applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191" ObJectlv&s and actlvltles Our purpose Pancreatic Cancer Action works lo save lives through promob.ng earfier diagnosis of pancreatic cancer. Vve do this through promoting greater awareness of the symptoms of the disease, the funding and development of mèdical èducational programmes, supporting patients through improved infomation about pancreatic cancer either on our website or in print and by funding research. Our vlslon Our vision is that everyone survives pancreatic cancer. Our ml$$lon Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed earfy and that everyone has access to effective treatments, support, infomiation and care. Objectives The charity's objectives are.. Awareness increase publi¢ awareness and knowledge of pancreatic can¢er and its symptoms lo achieve early diagnosis Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer Train and provide pioneering educational resources for our medical and healthcare communities Innovative research we fund it, we support il to improve early diagn0515 and develop effective treatments to Improve pancreatic cancer outcomes Offer the provision of practical and emotional support and information to all affected by pancreatic cancer Now - we are the action charity and action is needed more than ever beforel The Trustees have paid due regard lo guidance issued by the Charity Commission in deciding what activities the charity should undertake. The Trustees, actlvltles The Trustees meet regularly to develop and SUPPDrt strategies to meet the charitable objectives. The Trustees currently have a range of skills and experience that range from medicallscientific, legal, corporate governance, finance and PR. Role of volunteers I PCA Action Ambassadors The Charity reiVeS the very welcome assistance of volunteers. who help support a range of projects lo raise awareness of pancreatic Canr, provide support, review literature and fundraise in their communities. The charity seeks volunteer assistance via the website, social media and by word of mouth. Publlc benefit statement The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidan on public benefit.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Achievements and perfomianc Using some of our objedives as headings and some other key areas not covered above, we have sel wl below highlights of activity and work in 2023 in our ongoing mission lo improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access lo effective Ireatmenls, suppcrt, information and care. f. Awareness - increase public awarone$$ and know19dge of pancreatic cancor and its $ymptoms to achieve early diagnosis Throughout the year Pancreatic Cancer Action provided individuals, communities and organisalions wf(h resources lo help raise and improve symptom awareness of Britain's dèadliest cancer. Vve did this through providing posters, leaflets, booklets, online resources, and occupational health talks. In our mission lo improve early diagnosis and save lives, symptom awareness is key lo ensuring that people approach their GP for support. As well as providing these resou$ to individuals and communities free of charge, Pancreatic Cancer Action also took proactive and innovative steps to raise awareness with different communities and target those hard-to- reach groups. This included attending the Health & Wellbeing at Work Show on 14-15 March 2023 al the NEC Bimiingham. This was an opportunity for us lo promote our occupational health reSoUrS to organisalions and companies both large and small. Cancèr is a significant and growing issue In the workplace and il also has 8 significant impact on the economy. Issues like cancer can be very difficu lo discuss In the workpL? so through attending the Health & Wellbeing at Work Show we were able lo educate employers about the need lo properly support their employees who might have suspicions of cancer or are going through cancer treatment and just as importantly we were able to provide them with resources and an offer of occupational health training for their employees. Following on from our success the previous year in reaching out lo communities who do not have English as their first language, we took further steps to update our translated online and print health education resources. This meant we could providè quality accredited health information to those who have Polish. Urdu, Punjabi, Bengali, Arabic or Gujarati as their first language. These updates included highly trained medical professionals with their own first language experience reviewing the medical advice lo ensure il was up lo dale and accurate. Not being content with waiting for people with concerns to seek out support, as part of our ongoiry Action on the Ground project we sought Dut communities with a low health literacy lo provide them with symptom awareness resources. This included partnering with The Women's Integration Netr0rk in Glasgow to deliver an education talk and provide copies of a "Quick Guide to Pancreatic Cancer" In both Arabic and Urdu lo the large number of non-native English speakers who are part of the Women's Integration Network. Vve also partnered with the Coalfields Regeneration Trust to specifically largel men In former mining communities where heatth literacy is low. This partnership resulted in the production of symptom-awareness beer mats that were distributed to pubs and working men's clubs in areas of high deprivation. The chance of developing pancreatic cancer unfortunately increases with age and therefore we mLJSt take action to reach out to educate older people on the symptoms of pancreatic cancer. One of the ways we did tkis in 2023 was sharing 10,000 symptom awareness leaflets at Gardeners Worfd Live. The demographics of those who attend this event skew older and are more likely lo need this essential information that could save their lives. We also vi511ed a number of older people'5 groups lo deliver symptom awareness talks and provide leaflets to them. Pancreat1¢ Cancer Awareness Month or PCAM in November is normally our best opportunity to get key health information out there to the public and improve symptom awareness. 2023 was the blggest dlgltal symptom awareness campaign ever delivered by Pancreatic Cancer Action. We reached more people than ever before through our innovative and groundbreaking # missed campaign. Through the hashtag missed campaign, we sought to highlight all those who passed away from pancreatic cancer because their symptoms were missed. These symptoms were either missed by healthcare professionals or by the individuals themselves. Collaborative campaigns with Purple Llghts UK and The World Pancreatlc Cancer Coalition continue to see locations across the worfd light up purple to raise awareness during November and in particular on World Pancreatlc Cancer Day. This is largely a supporter focused campaign and has evolved lo include supporters lighting up their towns in support. as well as buildings and landmarks.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Pancreatic CancerAclion had a presence at Glasgow Central Slalion on World Pancreatic Cancer Day, arranged by one of our amazing supporters and Network Rail. We are grateful lo our volunteers and team members that helped make the day a huge Suc$$, with music from The Glasgow Rock Choir and various performers throughoLrt the day helping attract lots of attention. Information was shared rith commuters and visitors to the station, with a collection of generous donations. 2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer. As a small charity. we punch well above our weight when influencing governments and campaigning to win changes that ¥MII improve early diagnosis and save lives. Since launching a new mpaIgning and influencing strategy in 2021 we have seen significant steps forward in all Four Nations lo improve early diagnosis. Early in 2023, we worked with a number of bodies lo submit proposals to the National Cancer Board that would take further innovative steps to improve early diagnosis of pancreatic cancer in England. These proposals included.. Expanding Targeted Lung Health Checks lo cover Pancreatic Cancer- Al risk cohorts will be offered an extra scan of the area covering the kidney and pancreas and il only adds 10 -15 seconds to the procedLJre. Pancreatic Cancer Surveillance Coordinators to meet NG85 NICE guidan. 10°A of cases are linked lo genetic risk factors. Coordinators will implement high-risk Surveillan protocol to identify these people and enrol them on annual surveillan New case finding protocol for panc811¢ cancer in patients with New Onset Diabetes and weight loss. A new algorithm to identify these patients faster and speed up diagnosis Enable direct referrals into urgent canr pathways andlor testing from a cenlralised Servi {such as NHS 1111 Cutting the strain on Primary Care, this is an additional roule to diagnosis for those with a combination of 'vague' and 'non-descripl' symptoms. We were very pleased when the National Cancer Board adopted all of these proposals and al the lime of writing these projects are in the process of being piloted. As an organisation, we have continued to be heavily involved in shaping and delivering some of these projects including the new case-finding protocol for pancreatic cancer patients with new onset diabetes and weight loss. We have worked with NHS England and the University of Surrey to develop this project, identify partners, and create a pilot before any further rollout acruss England. We have met as a group once every four to six weeks so we can manage the progress and ensure there are no delays in getting this up and running. We've continued lo seek lo change the key areas of our healthcare system lo improve support and ¢¥e for pancreatic cancer patients. One way we do this is through SLJbmitting consultation responses to governments and public bodies. In 2023 this included bul was not limited to responses to the National Cancer Strategy for England (now the major conditions strategy) the Scottish Cancer Strategy and Action Plan and the NICE suspected cancer consultation. Our consultation responses resulted in governments adopting new proposals to improve early diagnosis of pancreatic cancer. For example, induded in the Scottish Cancer Action Plan published alongside the final strategy il included 8 commitment lo exploring the ways community phanaciSts can support the diagnosis of cancer. This has long been an area of work for Pancreatic CancerAclion and was a key part of our submission lo the strategy consullalion. In order to advan and promote our policy proposals in Scodand that had already been adopted in England, we attended the Scottish Conservative Party conference and the Scottish Labour Party conference in the spring. (There was no spring SNP Conference). Members of the team met with MSPS, MPS and councillors lo explain the priorities of Pancreatic Cancer Action and why we needed to take action lo improve the [vIVal rale of pancreatic cancer. During the conferences, we also asked politicians to help us raise awareness of pancreatic cancer symptoms wthin their communities.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Throughout the year we networked and promoted our policy proposals to politicians and health leadws across the UK. In the run-up to the annual Pancreatlc Cancer Awane$S Month debate at the Scottlsh ParllamenL we provided briefings lo all MSPS on the key issues patients and their families fa in Scotland and our proposals to improve earfy diagnosis and save lives. We also offered MSPS the opportunity to meet with a member of the team and our supporters. As a charity, we attended the annual Scottish Cancer Conference. The Conferen allows us an opportunity to speak directly wth health leaders and promote our accredited education and training for healthcare professionals as well as sharing our priorities for patients. Coming out of the conference il was clear that there is growing support wthin the wider healthcare community for some of the proposals we're putting forward to improve eady diagnosis and save lives. We continue to work in partnorship with the Scottish Cancer Coalition, the Less Survivable Cancers Taskforce, the North Cancer Alliance Iscotlandl, Cancem INorth East Englandl, Cancer 52, One Cancer Voice and a number of other coalitions of cancer charities. This partnership working slrenglhens our voice and makes sure that patients, voices are put at the heart of decision-making by politicians and governments. We continue to be a key partner in the delivery of The SHPBN Pathway Improvement Project Inow called SCOT-HP81. This is delivered by the Scottish Government, NHS Scotland, and cancer charities and parb)ers such as ourselves. Pancreatic Cancer Action have been leading on the patient and public involvement aspect of the project that is already seeing results and redLJcing the lime from suspiryon lo treatment and care for pancreatic cancer patients. 3. Train and provide pioneering educational resources for our medical and healthcare communities. Pancreatic Cancer Action provides accredited e-learning for GPS, Pharmacists and Pharmacy Teams. Our GP e-leaming, hosted by The Royal College of General Practitioners IRCGPI was updated during the year. Various webinars were hosted with neorkS induding members of RCGP Wales and The Wessex Canr Allian. We continue to provide GP and Phamiacy packs across the UK and thank our community of volunteers who help disseminate information on our resources in their local communities. 4. Innovative research we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes. As a small Charity with limited funds, we are not able lo invest millions into research, the same as larger organisalions. However. by also being a small Charity we are able lo be more innovative and invest, kickslart, pump prime and support research that has the potential lo save lives that might have been looked ov¥ by other organisalions and much larger funders. In anticipation of relaunching our Early Diagnostic Challenge Award in 2024, Pancreatic Cancer Action rejoined The Association of Medical Research Charities also known as The AMRC. The association provides support and advice lo charitiès such as our own when making research grant awards. Since rejoining the association, staff members have partaken in AMRC hosted training lo prepare us for the relaunch of the eady diagnostic challenge award in 2024. We continued to be an active partner in the research project we previously funded with a University of Surrey research team led by Dr Agnieszka Lemanska. The aims Df the study were lo confimi the link between dabetes and pancreatic cancer and to examine the differences in diabetes management and primary care presentation between patients who go on lo develop pancreatic cancer and those who do not. The project was a retrospective case-conlrol study, Interrogating the RCGP database lo provide a large sample size of cases and controls. Multiple variables can be examined from demographics lo diagnostics, number of presentations at primary care to disease management. The project involves examining the GP records of patients with diabetes who went on to develop pancreatic cancer and those who did not develop the disease. Records will be taken from the RCGP database where approximately 9.5 million patients, data are stored. This allows a large sample of patients to be investigated. We have now supported the next stages of the research as we take its findings and implement the new case-finding protocol mentioned above. Pancreatic Cancer Action have been key in leading the patient and public involvement aspect of this work and making sure patients, voices are al the heart of the decEion-making process. In order to continue lo support this research the team at Pancreatic Cancer Action has supported continuing funding applicatlOll5 from the University of Sutrey lo ensure our seed-funded research ha5 an even bigger impact.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Members of the team attended the Preventlon Research Conference in Edinburgh and were able to speak lo academics, scientists, health leaders and politicians about our research and the impact il has had so far. 11 was also an opportunity lo inform partners about the plans lo relaunch the Eady Diagnostic Challenge Award. 5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer. One of the key ways we offer support lo patients and their families is through our patient and health Information booklets. Our booklets cover a wide range of topics to ensure that patients and their families are getting the support and advice they need. These booklets are provided free of charge and are regulady ordered by both individuals and organisalions such as hospitals and cancer Cenlres. 2023 saw a 33 increase in the demand for our patient and health infomiation booklets. This meant we were reaching more people than ever before with our accredited hIgtrqua1itY support information. Each one of the booklets is independently assessed and accredited by the Patient Information Forum and reviewed by highly trained medical professionals. The booklets are also complemented by our groundbreaking recipe book, which continues to be in high demand amongst patients and also continues lo be provided free of charge thanks lo the generous support of our donors. We continue lo look al how we can expand our offer and range of support for patients and their faffilies going through an incredibly difficult lime. One way in which we are looking lo ensure comprehensive coverage of support information is throLJgh the creation of new patient and health infomiation booklets. As a result, 2023 saw a new genetics booklet and a new booklet for patients and carers begin production. Creating new world- class accredited health information is a long process dLJe to the need to involve and consult medical professionals peer reviewers, lay reviewers, patients and their families, health leaders and other charitable organisalions. However, this process Is necessary to ensure we can provide the best possible support lo the people who need us most. One of the key and most practical ways we can offer support lo patients is through the funding we provide for a Cllnlcal Nursg Speclallsl based al Glasgow Royal Infirmary. Our supporters, fundraising has enabled this post since 2019 and since then they have supported hundreds of individuals. patients. family members. colleagues and members of the public through their work. 2023 began with a new person being appointed to the rde and as part of the Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infimiary, they help to suppcrt over 230 patients per year. This workload indudes interactions with patients in environments such as oulpalient clinics, endoscopy, waid inpalienl areas and telephone clinics. The Pancreatic Clinical Nurse Specialist team al Glasgow Royal Infirmary has over 2,500 Interactions with psb.enls every year across their work at return clinics, weèkly consultant clinics, and weekly nurse-led clinics. In 2023 we hosted our firsl°Purple Hearts Gathering. in Glasgow, providing a relaxed afternoon for our wonderful community of supporters. volunteers and stsff lo engage and Connect during November's Pancreatic Cancer Awareness Month. Fundraising In 2023, income was generated through a wde range of fundraising activities and donations, including our amazing supporters tsking part in challenge events, hosting fundraising activities in their communities and incredible support from corporates. A significant event in the year was the Just Employment Law Summer Ball raising over £120,000 in June 2023. We are forever grateful for their ongoing support and Charity partnership with Pancreatic CancerAclion. Substantial legacies were bequeathed to our charity in 2023 and we value the kind generosity of ppnple affected by pancreatic cancer. We are continually inspired by the energy, enthusiasm and commitment of our supporters who are determined to change the pancreatic cancer story and save more lives through early diagnosis. From dress down days in schools and workplaces. cake stalls, coffee mornings, bingo nights. charity dances, goll days, to distance challenges running, walking. smrimming and climbing. our supporters continLJally put the fun into fundraising and embracing the coloLJr purple, to help raise awareness and ftjnds for pancreatic Canr. THANK YOU- we are so grateful for all you do.
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Trusts and grants We are very grateful lo the many funders that give so generously towards our initiatives. activities and projects. In 2023 these included £5,000 of unrestricted grants and £57,260 of restricted grants. Flnanclal revlew The results for the year are summarised in the Statement of Financial Activities on page 15. The Trustees are pleased lo report that the charity's incoming resources for 2023 amounted lo £752,50412022". £488,089), 12021." £754,217), 12020." £1,256,477", an exceptional year which included a on&off transfer of £607.560 due to the merger with Pancreati¢ Cancer Scotland and £58,781 through the Coronavirus Job Retention Schemel12019: £786,5051,12018: £892,8511,12017'. £757,812). The Trustees would like to thank all those volunteers, fundraisers and donors corporate, trusts and foundations, as well as individual donors who have Supported the charity over the past years and upon whom we are dependent. Total spending on charitable activities was £465,441 12022". £450,195), 12021." £513,874}, 12020. £437,838) 12019. £609,931112018'. £669,1871,12017. £669,077). The charity achieved a net loss for the year of -£8,077 {2022.' £-241,7411, 12021.. £-87,7401, 12020.. £510,025) 12019. £-115,305112018. £-24,634112017. £-169,3151. Resgrves poll¢y 11 is the policy of the charity that unreslricled funds which have not been designated for a specffic use should be maintained to cover al least 6 months of operating expenditure. The Trustees consider that reserves al this level will ensure that, In the event of a significant diop in funding, they will be able lo continue the charity's current activities while consideration is given to ways in which additional funds may be raised. At 31st December 2023. the charity held reserves of £592,379 of which £283,789 was reslricled. Free reserves stood at £308.590 which is in line wrth the level of the reserves policy established by the board. Struure. govemance and management The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and ils charity numbers are 1137689 (England and Wales) and SC049777 Iscotlandl. The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were". H Matthews N Menezes N Mumford S Krag H Goodfellow L Condron D Georgiou R Legg C Carter E Cowan N Longworth L Nylander G Codacci Pisanelli D Slater G Lesca (Resigned 17 March 20241 (Resigned 18 March 20241 (Resigned 23 May 20231 (Resigned 12 June 20241 (Resigned 15 July 20241 (Resigned 2 July 20231 (Appointed 18 March 20241 (Appointed 18 March 20241 (Appointed 18 March 20241
PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 None of the Trustees has any beneficial interest in the charity. The members of the company guarantee lo contribute £10 in the event of liquidation. The Trustees continue to keep the Charity's activities under review, pacularlY rith regard to Y major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of intemal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated. Ststement of Trustees. responsibilities The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees, Report and the financial stslemenls in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Praclicel. Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the stale of affairs of the charity and of the incoming resources and application of resources, including the Income and expenditure, of the charitable company for that year. In preparing these financi81 stslemenls, the Trustees are required lo.. select suitable accounting policies and then apply them consistently., observe the methods and principles in the Charities SORP., make judgements and eslimales that are reasonable and prudent., slate whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial slalements., and prepare the financial slalements on the going concern basis unless il is inappropriate lo presume that the charity will continue in operation. The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any lime the financial position of the charity and enable them lo ensure that the financial slalements comply with the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005 and the Charities Accounts Iscollandl Regulations 2006 las amended). They are also responsible for safeguarding the assets of the charity and hence for taking ieasonable steps for the prevention and detection of fraud and other itregularilies. Auditor In a¢cordan¢e with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put al a General Meeting. The Trustees. report was approved by the Board of Trustees. G Codaccl Pl$ano111 Chair of Trustees Dated.. 231.0912024
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF PANCREATIC CANCERACTION Oplnlon We have audited the financial statements of Pancreab'c Cancer Action (the 'charity'l for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial slatemenls, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporb"ng Standard 102 The Financial Reporting Standard applicable the UK and RepublK of Ireland Iuniled Kingdom Generally Accepted Accounting Praclicel. In our opinion, the financial slatemenls.. give a true and fair view of the slate of the charitable company's affairs as at 31 December 2023 and of its incoming resou$ and application of resou$. for the year then ended.. have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practi,. and have been prepared in accordance ¥Mth the requirements of the Companies Act 2006. the Charities and Trustee Investment (Scollandl A¢t 2005 and regulation 8 of the Charrties Accounts (Scollandl Regulations 2006 las amended). Basls for oplnlon We conducted our audit in accordance with International Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are further described In the Audilorts Sponsibl1111eS for the audit ol the financial slalements section of our report. We are Independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Stsndard. and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtsined is sufficient and appropriate lo provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements, we have conduded that the Trustees, use of the going cOnM basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating lo events or conditions that, Individually or collectively, may cast significant doubl on the charity's ability lo continue as a going concern for a period of at least twelve months from when the financial slalements a authorised for issue. Our responsibilities and the responsibilities of the Trustees rith respect to going concern are described in the relevant sections of this report. Other Infomiatlon The other information cornprises the information induded in the annual report other than the finamial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial stslemenls does not cover the other Information and we do not express any form of assurance conclusion Ihereon. Our respon5ibilily is lo read the other Inforrnation and, in doing so, consider whether the other information is materially inconsistent wlh the financial slalements or our knowledge obtained in the course of the audit. or otheMise appears to be materially misstated. If we identify such malerk81 inconsistencies or apparent material misstslemenls, we are required lo determine whether this gives rise to a material misstslemenl in the financial ststements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this Dther information, we are required to report that fact. We have nothing to report in this regard.
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF PANCREATIC CANCERACTION Matters on whlch we are requlred to report by exceptlon We have nothing to report in respect of the followng matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts {Scotlandl Regulations 2006 las amended) require us to report lo you if, in our opinion.. the information given in the financial slalemenls is inconsislenl in any material respect wth the Trustees, report., or sufficient and proper accounting records have not been kept., or the financial slalements are not in agreement with the accounting records", or we have not received all the information and explanations we require for our audit. Responslbllltles of Trustees As explained more fully in the statement of Trustees, responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial slalements and for being satisfied that they give a true and fair view, and for such Internal control as the Trustees determine is necessary lo enable the preparation of financial statements that are free from material mi5Statemenl, whether due lo fiaud or error. In preparing the financial slalemenls, the Trustees are responsible for assessing the charity'5 ability to continue as a going concern, disclosing, as applicable, matters related lo going concem and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitsble company or lo cease operations. or have no realistic altemalive but to do so. Audltor's responslbllltles for the audlt of the flnanclal ststements We have been appointed as auditor under section 144 of the Charities Act 2011 and section 4411 Ilcl of the Charities and Trustee Investment IScoUandl Act 2005 and report in accordan with the Acts and relevant regulations made or having effect Ihereunder. Our objectives are lo obtain reasonable assurance about whether the financial slalements as a Wha are free from material misslatemenl, whether due to fraud or error, and lo issue an audilorfs report that includes our opinion. Reasonable assurance is a high level of assurance bul is not a guarantee that an audit conducted in accordance with ISAS IUKI will always delect a material misslalement when it exists. Misslatemenls can arise from fraud or error and are considered material rf. individually or in the aggregate, they could reasonably be expected lo influence the economic decisions of users taken on the basis of these financial slatemenls. Irregularities, induding fraud, are instances of non-compliance wich laws and regulations. We design procedures in line with our responsibilities, outlined above. to detect material misslalements in respect of irregularities, including fraud. The extent lo which our procedures are capable of delecling irregularities. including fraud. is detailed below. Extent to whlch the audlt was consldered capable of detectlng Irregularltles, Includlng fraud Our approa¢h lo identifying and assessing the risks of material misstslemenl in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows.. the engagement partner ensured that the engagement team collectively had the appropriate competen, capabilities and skills to identify or recognise non-compliance rith applicable laws and regulations., we identified the laws and regulations applicable lo the company through discussions with Trustees and other management, and from our knoedge and experience of the sector., we focused on specrfic laws and regulations which we considered may have 8 direct material effect on the financial slalemenls or the operations of the charitsble company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, laxalion legislation, data protection, anti-bribery, employment, environmental and health and safely legislation.. we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal Corresponden.. and • identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit. 10-
PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF PANCREATIC CANCERACTION We assessed the susceplibilily of the charitable company's financial slalemenls to material misslatemenl, including obtaining an understanding of how fraud might occur, by.. making enquiries of management as lo where they considered there was susceplibilily to fraud, their knowledge of actual. suspected and alleged fraud., and considering the intemal controls in place to mitigate risks of fraud and non-compliance with laws and regulations. Audit response to risks identified To address the risk of fraud through management bias and override of controls, we.. perfomied analytical procedures to identify any unusual or unexpected relationships., reviewed all transactions Iisled., assessed whethèr judgements and assumptions made in determining the accounting estimates were indicative of potential bias", and investigated the rationale behind signrficant or unusual transactions. In response to the risk of irregularities and non-¢omplian¢e with laws and regulations. we designed procedures which included. but were not limited to.. • agreeing financial statement disclosures to underfying supporting documentation,. and enquiring of management as to actual and potential liligalion and daims. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of norFcompliance. Auditing standards also limit the audit procedures required lo identify non<ompliance with laws and regulations ID enquiry of the Trustees and other management and the Inspection of regulatory and legal corresponden, if any. Material misslalements that arise due to fraud can be harder lo detect than those that arise from error as they may involve deliberate concealment or collusion. A further description of our responsibilities is available on the Financial Reporting Council's website al.. https'.11 w.fr¢.Org.k1audIt0rsresponslb1lltle$. This description forms part of our auditor's report. Other matters which we are required to address In the previous accounting period, the trustees took advantage of audit exemption under $477 of the Companies Act. Therefore, the comparative figures in respect of the prior period to 31 Dember 2022 were not subject to audit. This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required lo state lo them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility lo anyone other than the company and the company's members as body, for our audit work, for this report, or for the opinions we have formed. Slyl_ ALLIk Stephen Meredlth BA FCA DChA (Senlor Statutory Audltorl for and on behalf of Alliotts LLP 2310912024 Chartemd Accountsnts Ststutory Auditor 3 London Square Cross Lanes Guildford GU1 1UJ Alliotts LLP is eligible for appointment as auditor of the charity by virtue of ils eligibility for appointment as auditor of company under section 1212 of the Companies Act 2006.
PANCREATIC CANCER ACTION STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023 Unrestrlcted Restrlcted funds funds 2023 2023 Total Unrestrlcted Restrlcted funds funds 2022 2022 Totsl 2023 2022 Notes Donations and legacies other trading activities Investments 571,774 170,357 742,131 463,769 18,474 482,243 3,334 7,039 3,334 7,039 4,691 1,155 4,691 1,155 Total income 582,147 170,357 752,504 469,615 18,474 488,089 Raising funds 276,495 18,645 295,140 279,635 279,635 Charitable activities 288,539 178,902 485,441 322,026 128.169 450,195 Total expendlture 565,034 195,547 760,581 601,661 128,169 729,830 Gross transfers betrNeen funds 17 Net incomellexpenditurel for the yearl Net movement in funds 56,213 156,213} 17,113 {25,1901 18,0771 175,8331 1165,908} 1241,7411 Fund balances al 1 January 2023 291,477 308,979 800,456 367,310 474.887 842,197 Fund balances at 31 December 2023 308,590 283,789 592,379 291,477 308,979 600,456 The statement of finanaal activities indudes all gains and losses rewgnised in the year. All income and expenditure derive from continuing adivities. The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006. 12-
PANCREATIC CANCER ACTION BALANCE SHEET AS AT 31 DECEMBER 2023 2023 2022 Notes Fixed assets Tangible assets 12 364 Current assets Stocks Debtors falling due after one year Debtors falling due wrthin one year Cash at bank and in hand 13 14 14 3,675 333 78,865 545,716 3,875 2,333 72,275 584,729 628,589 663.212 Credttors- amounts falling due within one year 15 136,2101 163,1201 Net current assets 592,379 600,092 Total assets less current liabilities 592,379 600,456 The funds of the charity Reslricled income funds Unrestricted funds 17 283,789 308,590 308,979 291,477 592,379 600,456 The directors acknowledge their responsibilities for wmplying with the requirements of the Companies Ad 2006 with respect to accounting records and the preparation of financial statements. These financial stslemenls have been prepared in accordance wth the provisions applicable to companies subject to the small Companies regime. The financial stslemenls were approved by the Trustees on 2310912024 G Codacci Pisanelli Chair of Tru$tg9$ Company registration number 07272699 (England and Wales) 13-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 Accountlng pollcles Charity infomiation Pan¢reali¢ Canr Adion is a registered charity and a company inwrporaled by guarentee with no share capital. exempted under section 5 of the Companies Act 2006 from the reqLJirement to Ljse Limited" as part of its name. It is incorporated in England and Wales under registration number 07272699 and its registered office is Suite 3.10 Covault, Fullarton Road, Carnbuslang, Glasgow, G32 8YL. 1.1 Accounting convention The financial statements have been prepared in accordance with the charity's Stslemenl of RecommeTvJed Practice applicable lo charities preparing accounts wlh the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021. the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005, the Charities Accounts (Scotlandl Regulations 2006 las amended). FRS 102 "The Financial Reporting Stsndard applicable in the UK and Republic of Ireland" I'FRS 1021 and the Charities SORP 'Accounting and Reporting by Charities.. Ststement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021" (effective 1 January 20191. The charity is a Public Benefit Enlily as defined by FRS 102. The financial statements are prepared in slerfing, which is the functional currency of the charity. Monetary amounts in these financial stalernenls are rounded to the nearest £. The finanaal statements have been prepared under the historical cost convention, Imodffied to include the revaluation of freehold properties and lo indude investment properties and certain financial instruments al fair valuel. The principal accounting policies adopted are sel out below. 1.2 Going concern Al the lime of approving the financial slalements, the Trustees have a reasonable expectation that the charity has adequate resources lo continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial stslemenls. 1.3 Charitable funds Unrestricted funds are available for use al the discretion of the Trustees in furtherance of their Charitable objectives. Restricted funds are subject to specific conditions by donors or grantors as lo how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements. 1.4 Income Income is recognised when the charity is legally entitled to il after any Performan conditions have been met, the amounts can be measured reliably. and il is probable that income will be received. Cash donations are recognised on reipl. Other donations are recognised once the charity has been notified of the donation, unless performance condrtions require deferral of the amount. Income lax recoverable in relat40n to donations received under GiftAid or deeds of covenant is recognised at the lime of the donation. Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distributy'on, the amount is known, and receipt is expected. If the amount is not known, the legacy is Irealed as a contingent asset. Gifts of assets and services are recognised at market value to the charity. 14-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 A¢¢ounllng poll¢lg$ Icontlnuedl 1.$ Exp8nditurg Expenditure is recognised once there is a legal or constructive obligation lo transfer economic benefit lo a third paty, It is probable that a transfer of economic benefi15 will be required in selllemenl, and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The Costs of ea¢h activity are made up of the total of dir1 costs and shared Costs. including support costs involved in undertaking each adivity. Direct ¢osls attributable lo a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those aclivilEs on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use. Expenditure has been allocated between the main headings in the Stslement of Financial Activities on the basis of the type of activity lo which they relate, including irrecoverable V.A.T. Income and expenses have not been netted off. 1.6 Tangible fixed assets Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impaimient losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases.. Fixtures, fittings & equipment Computers 250/0 on cost 25% on cost The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the slalement of financial activities. 1.7 Impalrment of flx&d a$$gts Al each reporting end dale, the charity reviews the carrying amounts of its tangible assets to determinè whether there is any Indication that those assets have Suffered an impairment 105s. If any such Indication exists, the COverable amount of the asset is eslimaled in order lo determine the extent of the impaimenl loss lif any). 1.8 Stocks Stocks are slated al the lower of cost and eslimaled selling price less costs to COTllplete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks lo their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost. The charity are recognising 80% of the stock as free stock issues to support activities raising fd8 and awareness. The balance recognised on the balance sheet is the residual value of the stock. Nel realisable value is the estimated selling price less all esb"mated costs of completion and costs to be incurred in marketing, selling and distiibulion. 1.9 Cash and cash equivalents Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-lerm liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities. 15-
PANCREATIC CANCER ACTION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 A¢¢ounllng poll¢lg$ Icontlnuedl 1.10 Flnancial instrumanls The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments, and Section 12 'Olher Financial Instruments Issues, of FRS 102 to all of ils financial inslrumenls. Financial instruments are recognised in the charity's balance sheet when the charity becomes party lo the conlraclual provisions of the inslrumenl. Financial assets and liabilities are offset, with the net amounts presented in the financial slatemenls, when there is a legally enforceable right to sel off the recognised amounts and there is an intention lo settle on a net basis or to realise the asset and setue the liability simultaneously. Basic financial assets Basic financial assets, which include debtors and cash and bank balan8, are initially measured at transaction price including transaction costs and are subsequently carried al amortised cost using the effective interest method unless the arrangement conslilules a financing Iransa¢lion, where the Iransa¢lion is measured al the present value of the ftjlure receipts discounted al a market rale ol interest. Financial assets classified as receivable within one year are not amortised. 8aslc flnanclal liabilities Basic financial liabilities, including creditors and bank loans are initially recognised al transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured al the present value of the future payments discounted at a market rale of interest. Financial liabilities classified as payable wthin one year are not amortised. Debt instruments are subsequently carried al amortised cost, using the effective interest rale method. Trade creditors are obligations to pay for goods or setvices that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially al transaction price and subsequenuy measured at amortised cost using the effective interest method. Derecognition of financial liabilities Financial liabilities are derecognised when the charity's contractual obligations expire or are dischaTged or cancelled. 1.11 Employee benefits The cost of any unused holiday enlillement is recognised in the period in which the employee's services are received. Temiination benefits are recognised immediately as an expense when the charity is demonstrably committed lo terminate the employment of an employee or to provide termination benefits. 1.12 Retirement benefits Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due. 16-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023 2023 2022 Notes Cash flows from opgratlng a[VItIS Cash absorbed by operations 22 146,0521 1239,1551 Investing activities Investment income received 7,039 1,155 Net cash generated from investing activities 7,039 1,155 Net cash used in financing activities Net decrease in cash and cash equivalents 139,0131 1238,0001 Cash and ¢ash equivalents at beginning of year 584,729 822,729 Cash and cash equlvalents at end of year 545,716 584,729 17-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Crltlcal accountlng estlmatss and Judgements In the application of the charity's accounting policies, the Trustees are required lo make judgem1$, eslimales and assumptions about the carrying amount of assets and liabilities that are not readily appaienl from other sources. The eslimales and associated assumptions are based on historical experience and other factors that are considered lo be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects cnly that period, or in the period of the revision and future periods where the revision affects both current and future periods. Donations and legacies Unrestricted Restricted funds funds Total Unrestricted Restricted funds funds Total 2023 2023 2023 2022 2022 2022 Donations and gifts Legacies receivable Grants receivable for core activities 544,215 22,559 14,539 98.558 558,754 121,117 463,769 18,474 482,243 5,000 57,260 62,260 571,774 170,357 742,131 463,769 18,474 482,243 Other trading activities Unrestricted Unrestricted funds funds 2023 2022 Sales of merchandise 3.334 4,691 Income from investments Unrestricted Unrestricted funds funds 2023 2022 Interest receivable 7,039 1,155 18-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Ralslng funds Unrestricted Restricted funds funds Total Total 2023 2023 2023 2022 Fundraisin and Fundraising costs Staff costs Depreciation and impaimient Support costs 91,592 152,271 137 26,603 91,592 168,205 137 29,314 84,797 139,222 1,042 34,427 15,934 2,711 Fundraising and publicity 270,603 18,645 289,448 259,488 Tradin costs Olhei trading activits.es 5,893 5,893 20,147 276,495 18,645 295,140 279,635 Charitable activities Raising Supporting awarene55 research Medical education Patient 5UPPOrtI Infomiation 2023 Total 2023 Total 2022 2023 2023 2023 staff costs Depreciation and impairment Other costs 158,002 17,798 35,354 42,988 254,142 240,105 143 100,840 16 11,360 32 22,564 36 27,431 227 162,195 1,711 151,855 258,985 29,174 57,950 70,458 416.567 393,671 Share of support costs Isee note 91 Share of governance costs (see note 91 25,084 2,826 5,613 6,828 40,351 50,932 5,301 597 1,186 1,442 8,526 5,592 289,370 32,597 64,749 78,725 465,441 450,195 Analysis by fund Unrestricted funds Restricted funds 205,911 83,459 14.364 18,233 37,191 27,558 31,073 47,652 288,539 176,902 322,026 128,169 289,370 32.597 64,749 78.725 465,441 450.195 19-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Charltsblg a1¥1110$ Icontlnuedl For th9 ygar 9ndgd 31 D9¢9mber 2022 Ralslng Supportlng Medlcal awarene$$ reSeah educallon Patlent $upportl information Totsl 2022 staff costs Depreciation and impaimienl Other costs 188,938 1,346 119.338 3,839 27 2,391 18,338 131 12.070 28,990 207 18,056 240,105 1,711 151,855 309,622 8,257 30.539 47,253 393,671 Share of support costs Isee note 91 Share of governance costs (see note 91 40,079 4,401 814 89 3,890 427 6,149 675 50,932 5,592 354,102 7,160 34,856 54,077 450,195 Analysis by fund Unreslricled funds Restricted funds 253,382 100,720 4,620 2,540 32,316 2.540 31,708 22,369 322,026 128,169 354,102 7,160 34,856 54,077 450,195 Tru$teg$ None of the Trustees lor any persons connected with Iheml received any remuneration during the year and none of them were reimbursed Iravelling expenses12022- £Nill. -20-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Support costs Support Governance costs costs 2023 Support Governance costs costs 2022 Rent Office costs Telephone costs Computer Costs Insurance Training, recruilmenl and internship costs Book-keeping and Accountancy Bank charges 22,268 2,841 3,140 24,718 3,029 22,268 2,841 3,140 24,718 3,029 18,941 6.378 2,272 17,303 2,496 18,941 6,378 2,272 17,303 2,496 5,196 5,196 31,400 31,400 2,885 474 2,885 474 2,587 572 2,587 575 Audit fees Legal and professional 10,400 3,240 10,400 3,240 5,760 3,240 5,760 3,240 64,551 13,640 78.191 81,952 9,000 90,952 Analysed beeen Fundraising Charrtable activity'es 24,200 40,351 5,114 8,526 29,314 48,877 31,020 50,932 3,408 5,592 34,428 56,524 64,551 13,640 78,191 81,952 9,000 90,952 Governance costs include payments of £7,800 12022 - £5,760 for independent examination fees) for audit fees and £2,600 for accounts preparation fees. 10 Employ99$ The average monthly number of employees during the year was.. 2023 Number 2022 Number Employment costs 2023 2022 Wages and salaries Social security costs Other pension costs 380.476 32,403 9,468 339,477 29,650 10,200 422,347 379,327 There were no employees whose annual remuneration was more than £60,000. 21
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 11 Taxatlon The company is a registered charity and is, therefore, exempl from tsxation on ils charitable activities. 12 Tangible fixed assets Fixtures, fitting5 & equipment Computsrs Total Cost At 1 January 2023 10,612 12,245 22,857 Al 31 December 2023 10,612 12,245 22,857 Depreclatlon and Impalrnlent At 1 January 2023 Depreciation charged in the year 10.329 283 12,164 81 22,493 364 At 31 Dember 2023 10,612 12,245 22,857 Carrylng amount Al 31 Dernber 2023 At 31 Dember 2022 283 81 364 13 Stocks 2023 2022 Finished goods and goods for resale 3,675 3,875 14 Debtors 2023 2022 Amounts falling due within one year: Other debtors Prepayments and accrued income 12,076 60,199 78,865 78.865 72,275 2023 2022 Amounts falllng due after more than one year: Prepayments and accrued income 333 2,333 Total debtors 79,198 74,608 -22-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 15 Credltors: amounts falllng due wlthln one year 2023 2022 Other taxation and social security Trade creditors Accruals and deferred income 10,010 7,916 18,284 8,528 29,399 25,193 36,210 63,120 16 Rgtlrgmgnt bgneflt $¢h9mgS 2023 2022 Defined contrlbutlon schemes Charge to profit or loss in respect of defined contribution schemes 9,468 10,200 The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund. 17 Rfrstrlcled funds The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject lo specific conditions by donors as lo how they may be used. At 1 January 2023 Incoming rosour¢&s Resources exponded Transfers At31 Decembgr 2023 Pat & Paul POW app Recipe Book Patient Information Booklets NIPanC Translation of resources Research Pancreatic Cancer Swtland PC Aware North East England Action on the Ground Glasgow Project Community volunteers GP Packs 12,605 17,200 14,335 8,357 5,845 8,584 21,189 17,200 10,645 1,000 7,955 14,6901 116,3121 5,845 493 22,500 175.196 20,000 2,000 22,500 98,558 20,000 11,5071 247.677 1171,0391 9,760 9,760 960 960 2,000 12,0001 308,979 170,357 1195,5481 283,788 -23-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 17 Rgstrl¢led fund$ Icontlnuedl Prevlou$ year: At 1 January 2022 Incoming resourcgs Resource$ expended Transfers At31 Dgcgmber 2022 Pat & Paul POW app Recipe Book Patient Information Booklets Hope is Contagious NIPanC Pancreatic Cancer Scotland Community volunteers GP Packs 2,506 17.200 18,174 15,972 156 6,456 411.463 960 2,000 10,099 12,605 17,200 14,335 8,357 13,8391 115,9901 11561 16111 1107,5731 8,375 5,845 247,677 960 2,000 156,2131 474,887 18,474 1128,1691 156,2131 308,979 Restricted funds relate lo grants received for the specific purposes as set out above. Any amount unspent is carried foNard to be spent in the next financial year. No transfer between UnstrICted and reslricled funds has been made in the year ended 31 December 2023. 18 Analysis of net assets between funds Unrestrlcted funds 2023 Restrlctgd funds 2023 Totsl 2023 At 31 December 2023- Current assetsllliabililiesl 308,590 283,789 592,379 308,590 283,789 592,379 Unrestricted funds 2022 Restrictsd funds 2022 Total 2022 At 31 December 2022: Tangible assets Current assetsllliabililiesl 364 600,092 291,113 308,979 291,477 308,979 600,456 -24-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 19 Flnanclal commltments. guarantees and contlngent Ilabllltles To dale, the charity has received £46,897 in donations from solicitors relating lo old monies held in client accounts which they have not been able lo relum. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial slalemenls for any possible reftjnd as the likelihood is remote and cannot be quantified. The charity has committed lo sponsor a nursing post wthin NHS Greater Glasgow & Clyde IGGCI for a three year period which started in January 2023. The total commitment Over the next two years is expected to be £90,238 20 Operating lease commitments Lessee Operating lease payments in the prior year related lo office lease rental. The charity moved lo neN premises in the current year using licence agreements which provide shorter, more flexible tems. Al the reporting end dale the charity had oulslanding commitments for future minimum lease payments under non-can¢ellable operating lèases, which fall due as follows. 2023 2022 Within one year 4,320 21 Related party transactlons Remuneratlon of key management personnel The remuneration of key management personnel is as follows. 2023 2022 Aggregate compensation 58,599 56,393 The key management personnel of the Charity is considered to be the CEO. There were no other related party Iransaclions. -25-
PANCREATIC CANCER ACTION STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 22 Cash generated from operatlons 2023 2022 Deficit for the year 18,0771 1241,7411 Adjustments for.. Investment income recognised in statement Df financial activities Depreciation and impairment of tangible fixed assets 17,0391 364 {1,1551 2,753 Movements in working capital.. Decrease in stocks {Increasel in debtors IDecreasellincrease in creditors 200 14,5901 126,9101 14,536 124,0311 10,483 Cash absorbed by operations 146,0521 1239,1551 23 Analysis of changes in net funds The charity had no material debt during the year. -26-